

INPLASY202540058

doi: 10.37766/inplasy2025.4.0058

Received: 17 April 2025

Published: 17 April 2025

**Corresponding author:**

Jiaqi Ji

18981831998@163.com

**Author Affiliation:**

Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China.

## Risk Factors for Mortality in Anti-MDA5 antibody-positive Dermatomyositis with Interstitial Lung Disease: A Systematic Review and Meta-Analysis

Yang, YH; Li, Y; Yuan, WW; Zhang, SJ; He, X; Ji, JQ.

**ADMINISTRATIVE INFORMATION**

**Support** - Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China.

**Review Stage at time of this submission** - This work was supported by the National Natural Science Foundation of China (No. 82400093) and the Natural Science Foundation of Sichuan Province, China (No. 2025ZNSFSC1540).

**Conflicts of interest** - None declared.

**INPLASY registration number:** INPLASY202540058

**Amendments** - This protocol was registered with the International Platform of Registered Systematic Review and Meta-Analysis Protocols (INPLASY) on 17 April 2025 and was last updated on 17 April 2025.

**INTRODUCTION**

**Review question / Objective** This study aimed to explore the risk factors for mortality in patients with MDA5+ DM-ILD.

**Condition being studied** In Web of Science, PubMed, Embase and Scopus databases, a comprehensive search was performed for English studies on MDA5+, DM and ILD published from inception date until November 18, 2025.

**METHODS**

**Participant or population** 1153 Anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis with interstitial lung disease (MDA5+ DM-ILD) patients.

**Intervention** NonSurvival MDA5+ DM-ILD patients group.

**Comparator** Survival MDA5+ DM-ILD patients group.

**Study designs to be included** Retrospective.

**Eligibility criteria** The criteria for inclusion were as follows: (1) prospective or retrospective studies; (2) diagnosis of DM was based on the IIM classification criteria of the European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) or Bohan and Peter's diagnostic criteria ; (3) diagnosis of ILD was based on established clinical guidelines , incorporating respiratory symptoms, physical examination findings, abnormalities on high-resolution computed tomography (HRCT), and pulmonary function test results through multidisciplinary evaluation; (4) hazard ratios (HR) and 95% confidence intervals of mortality risk factors in MDA5+ DM-ILD were obtained by Cox

---

proportional hazards regression model; (5) English literature.

The criteria for exclusion were as follows: (1) duplicate literature; (2) case report, conference abstract, review or meta-analysis, animal or cell study, comment or letter etc.; (3) studies not related to MDA5+ DM-ILD. (4) mortality of MDA5+ DM-ILD is not the outcome event; (5) inability to extract data; (6) literature not in English.

**Information sources** A comprehensive search of English language literature published in PubMed, Embase, Web of science, and Scopus databases prior to November 18, 2025 was performed.

**Main outcome(s)** Risk factors for mortality.

**Quality assessment / Risk of bias analysis** The Newcastle-Ottawa Scale (NOS) was applied for the quality of the included literatures.

**Strategy of data synthesis** HR and 95% CI of risk factors were collected as statistical effect sizes, and Cochran's Q statistic and inconsistency value (I<sup>2</sup>) was used to test for heterogeneity of the included studies. If  $P < 0.05$  and  $I^2 \geq 50\%$ , heterogeneity was significant, and pooled analyses were performed using random effects model and Der Simonian-Laird (DL) method. Otherwise, fixed effects model and inverse variance (IV) method were used.

**Subgroup analysis** Subgroup analyses were executed for different risk factors.

**Sensitivity analysis** Excluding one category of study at a time method was utilized for sensitivity analysis.

**Country(ies) involved** China.

**Keywords** Anti-melanoma differentiation-associated protein 5; dermatomyositis; interstitial lung disease; mortality; poor prognosis.

#### **Contributions of each author**

Author 1 - Yahui Yang.

Author 2 - Ying Li.

Author 3 - Weiwei Yuan.

Author 4 - Shijie Zhang.

Author 5 - Xing He.

Author 6 - Jiaqi Ji.